David Stevens Net Worth

The estimated Net Worth of David R Stevens is at least $229 dollars as of 11 May 2023. David Stevens owns over 95,000 units of Ampio Pharmaceuticals Inc stock worth over $229 and over the last 13 years he sold AMPE stock worth over $0. In addition, he makes $0 as Independent Director at Ampio Pharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

David Stevens AMPE stock SEC Form 4 insiders trading

David has made over 1 trades of the Ampio Pharmaceuticals Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently he bought 95,000 units of AMPE stock worth $20,900 on 11 May 2023.

The largest trade he's ever made was buying 95,000 units of Ampio Pharmaceuticals Inc stock on 11 May 2023 worth over $20,900. On average, David trades about 4,130 units every 0 days since 2011. As of 11 May 2023 he still owns at least 103,971 units of Ampio Pharmaceuticals Inc stock.

You can see the complete history of David Stevens stock trades at the bottom of the page.

David Stevens biography

Dr. David R. Stevens Ph.D. serves as Independent Director of the Company. Dr. Stevens has served as a member of our Board since June 2011. Dr. Stevens has worked in the FDA regulated life science industries since 1978. He has also been a consulting research pathologist since December 2006 for Premier Laboratory, LLC. He has been a board member of Cetya, Inc. since December 2013. He has served on the boards of several other public and private life science companies, including Micro-Imaging Solutions, LLC (2007-2018), Poniard Pharmaceuticals, Inc. (2004-2013), Aqua Bounty Technologies, Inc. (2002-2012) and Smart Drug Systems, Inc. (1999-2006), and was an advisor to Bay City Capital (1999-2006). Dr. Stevens was previously President and CEO of Deprenyl Animal Health, Inc., a public veterinary pharmaceutical company, from 1990 to 1998, and Vice President, Research and Development, of Agrion Corp., a private biotechnology company, from 1986 to 1988. He began his career in pharmaceutical research and development at the former Upjohn Company, where he contributed to the preclinical evaluation of Xanax and Halcion. Dr. Stevens received B.S. and D.V.M. degrees from Washington State University, and a Ph.D. in Comparative Pathology from the University of California, Davis. He is a Diplomate of the American College of Veterinary Pathologists.

How old is David Stevens?

David Stevens is 70, he's been the Independent Director of Ampio Pharmaceuticals Inc since 2011. There are 2 older and 8 younger executives at Ampio Pharmaceuticals Inc. The oldest executive at Ampio Pharmaceuticals Inc is Philip Coelho, 75, who is the Independent Director.

What's David Stevens's mailing address?

David's mailing address filed with the SEC is 300 ELLIOTT AVENUE WEST, SUITE 500, SEATTLE, WA, 98119-4114.

Insiders trading at Ampio Pharmaceuticals Inc

Over the last 13 years, insiders at Ampio Pharmaceuticals Inc have traded over $202,762 worth of Ampio Pharmaceuticals Inc stock and bought 377,748 units worth $116,063 . The most active insiders traders include Philip H Coelho, Joshua R. Disbrow, and J Kevin Buchi. On average, Ampio Pharmaceuticals Inc executives and independent directors trade stock every 192 days with the average trade being worth of $74. The most recent stock trade was executed by J Kevin Buchi on 9 June 2023, trading 21,858 units of AMPE stock currently worth $6,339.

What does Ampio Pharmaceuticals Inc do?

ampio pharmaceuticals inc (ampe) is a biotechnology company located in 5445 dtc pkwy, greenwood village, colorado, united states.

Complete history of David Stevens stock trades at Ampio Pharmaceuticals Inc

Ampio Pharmaceuticals Inc executives and stock owners

Ampio Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Michael E. Macaluso,
  Founder, Chairman & CEO (Leave of Absence )
• Daniel G. Stokely CPA, CPA,
  CFO, Corp. Sec. & Treasurer
• Holli Cherevka,
  Chief Operating Officer
• Daniel Stokely,
  Chief Financial Officer, Treasurer, Secretary
• Michael Macaluso,
  Chairman of the Board, Chief Executive Officer
• Holli Cherevka,
  Pres & COO
• David Bar-Or,
  Director
• David Stevens,
  Independent Director
• Richard Giles,
  Independent Director
• Philip Coelho,
  Independent Director
• Laura Goldberg,
  VP of Quality and Regulatory Operations
• April Ramirez,
  Clinical Trial Mang.
• Lane Hapke,
  VP of Manufacturing Operations
• Dr. Howard Levy M.B.B.Ch., M.M.M., Ph.D.,
  Chief Medical Officer
• Michael A. Martino,
  CEO & Chairman
• Michael A Martino,
  CEO
• J Kevin Buchi,
  Director
• Vaughan Lennox Clift,
  Chief Regulatory Affairs
• Gregory A Gould,
  Chief Financial Officer
• Iii Thomas E. Chilcott,,
  Chief Financial Officer
• Dan Stokely,
  CFO
• Mark D Mc Gregor,
  Chief Financial Officer
• Joshua R. Disbrow,
  Chief Operating Officer
• Elizabeth Varki Jobes,